Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,227 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

NCT01689155
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

ANTI-TAC THERAPY FOR UVEITIS

NCT00001526
View directory record Official record
Conditions
Uveitis
Interventions
Daclizumab (Zenapax)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use

NCT03502525
View directory record Official record
Conditions
Substance Abuse, Intravenous, Prevention and Control
Interventions
Break the Cycle Intervention, Bacterial Infection Prevention
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 4 Interventional Results available

Anti-HIV Medications for People Recently Infected With HIV

NCT00106171
View directory record Official record
Conditions
HIV Infections
Interventions
Highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 4 Interventional

Daily Chlorhexidine Bathing and Infection Rates in Critically-ill Patients

NCT02033187
View directory record Official record
Conditions
Healthcare Associated Infections
Interventions
Chlorhexidine bathing, Non-chlorhexidine bathing
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 26, 2026, 9:30 PM EDT
Completed No phase listed Observational

Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice

NCT00617006
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

NCT00678106
View directory record Official record
Conditions
Bacterial Infections
Interventions
Dalbavancin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 26, 2026, 9:30 PM EDT
Completed No phase listed Observational

A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

NCT03769558
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Months and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 26, 2026, 9:30 PM EDT
Not listed Not applicable Interventional

Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes

NCT05287438
View directory record Official record
Conditions
Penile Implantation, Infections
Interventions
Next-Generation DNA Sequencing, Standard Culture
Diagnostic Test
Lead sponsor
MicroGenDX
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Bossier City, Louisiana • Raleigh, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HIV Prevention Intervention for Young Transgender Women

NCT01575938
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
HIV prevention intervention, Diet and Nutrition
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
16 Years to 29 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Antibiotic "Dysbiosis" in Preterm Infants

NCT02784821
View directory record Official record
Conditions
Enterocolitis, Necrotizing, Bacteremia, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia, Chronic Lung Disease, Ileal Perforation
Interventions
Antibiotic, Gastric fluid, Breast milk, Stool samples, Antibiotics
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

NCT03379506
View directory record Official record
Conditions
HCV Infection
Interventions
EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

NCT04335084
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Sars-CoV2, Corona Virus Infection, COVID, Coronavirus, Coronavirus-19, Coronavirus 19
Interventions
Hydroxychloroquine, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

NCT00000984
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

NCT07704333
View directory record Official record
Conditions
Aspergillos, Mucormye, Dimorphic, Other Molds, Non-Aspergillos, Non-Mucormycosis
Interventions
[18F]-Fluorocellobiose ([18F]FCB)
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

NCT00006133
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Not applicable Interventional

Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas

NCT06427538
View directory record Official record
Conditions
Empyema, Pleural, Pleural Infection
Interventions
Saline Flush
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Sterling Heights, Michigan • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed No phase listed Observational

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140
View directory record Official record
Conditions
Latent Tuberculosis Infection, Tuberculosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
21,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

NCT02510404
View directory record Official record
Conditions
Refractory Viral Infections
Interventions
mCTLs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 1 Interventional

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649
View directory record Official record
Conditions
HCV Infection
Interventions
VCH 916, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Coronavirus-specific T cell (CST)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients

NCT00000863
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
12
States / cities
Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 26, 2026, 9:30 PM EDT